Veeva Systems announced that more than 125 customers worldwide are now live on its Vault CRM platform, the company’s industry‑specific customer‑relationship management solution. The milestone includes top‑tier biopharma clients across the U.S., Europe and Japan, underscoring broad adoption of the platform’s integrated, compliance‑ready workflows.
The announcement is part of Veeva’s strategy to move customers from legacy Salesforce tenants to Vault CRM. Management expects the number of live customers to reach 200 by May 2026, a target that signals a rapid acceleration of the migration program that began in 2025 and is slated to complete by 2030.
Veeva’s Q1 2026 results—$759 million in revenue, up 17% year‑over‑year, and a non‑GAAP operating margin of 46.1%—provide a strong financial foundation for the rollout. The company also raised its full‑year guidance, reflecting confidence in continued growth of its cloud‑based services.
Key pharmaceutical customers that have committed to Vault CRM include GSK, Bristol Myers Squibb, Novo Nordisk, Gilead Sciences, Boehringer Ingelheim, Merck, and Roche, which selected the platform as its global solution in November 2025. These commitments illustrate the platform’s appeal to the largest players in the life‑sciences market.
Veeva’s end‑of‑support date for its legacy CRM, built on Salesforce, was moved from September 2030 to the end of December 2029, creating a clear deadline for customers to transition. The company’s focus on AI—through Veeva AI—further differentiates Vault CRM and positions it as an “agentic” solution that can drive higher customer engagement and operational efficiency.
The migration strategy is a core part of Veeva’s long‑term plan to consolidate its offerings on a single, cloud‑native platform. By reducing reliance on Salesforce, Veeva gains full control over its product roadmap, pricing, and innovation cadence, strengthening its competitive edge against Salesforce’s own Life Sciences Cloud and other industry players such as IQVIA and Oracle.
While the announcement does not provide specific go‑live dates for each customer, the fact that 125+ customers are already live as of March 3 2026 demonstrates tangible progress toward the company’s migration goals and signals momentum in a market that is increasingly demanding compliance‑ready, AI‑enabled CRM solutions.
The milestone also reflects broader market dynamics: the life‑sciences CRM market is projected to grow significantly, and AI‑powered CRM is expected to be a major growth driver. Veeva’s early adoption by top biopharma firms positions it well to capture this expanding opportunity.
Overall, the 125‑plus live customer count is a material event that highlights Veeva’s strategic shift, strengthens its competitive positioning, and supports its financial outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.